

## FGL1 Protein, Cynomolgus (HEK293, His)

Cat. No.:	HY-P72642
Synonyms:	Fibrinogen like 1; FGL1
Species:	Cynomolgus
Source:	HEK293
Accession:	A0A2K5X990 (L23-I312)
Gene ID:	102118020
Molecular Weight:	Approximately 35 kDa

### PROPERTIES

AA Sequence	<pre> LEDCAQE QVR   LRAQVRLLET   RVKQQQVKIK   QLLQENEVQF LDKGEENSVI   DLGSKRQYAD   CSEIFNDGYK   LSGFYKIKPL QSPAEEFAVYC   DMSDGGGWTV   IQRRSDGSEN   FNRGWNDYEN GFGNFVQKHG   EYWLGNKNLH   FLTTQEDYTL   KIDLADFEKN SRYAQYKNFK   VGDEKNFYEL   NIGEYSGTAG   DSLAGSFHPE VQWWATHQRM   KFTWDRDHD   NYDGNCAEED   QSGWWFN RCH SANLNGLYYT   GPYTAKTDNG   IVWYTWHGWW   YSLKSVVMKI RPNDFIPNVI           </pre>
Appearance	Solution.
Formulation	Supplied as a 0.2 µm filtered solution of 20 mM Tris, 300 mM NaCl, 10% Glycerol, 2 mM EDTA, pH 8.0.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconstitution	N/A
Storage & Stability	Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
Shipping	Shipping with dry ice.

### DESCRIPTION

Background	<p>Fibrinogen like 1 (FGL1), also known as HFREP-1 or hepassocin (HPS), is a proliferation- and metabolism-related protein secreted by the liver. FGL1 is a newly emerging checkpoint ligand of lymphocyte activation gene 3 (LAG3). When binding to LAG3, it can inhibit T cell activation and proliferation. Therefore, FGL1 can potentiate anti-tumor T cell responses and can be used for research of immune checkpoint therapy. Apart from the high expression in the liver, FGL1 is also upregulated in tumor tissues (such as lung, prostate, melanoma, colorectal, breast and brain tumors) and mediates EMT process. FGL1 is</p>
------------	---

---

an approxiamte 68-KD protein comprised of a disulfide bond-linked homodimer<sup>[1][2][3]</sup>.

Besides, as a liver protective factor, FGL1 accelerates the growth of liver cells by promoting mitochondrial mitosis in the event of liver injury. FGL1 plays a role in proliferation, metabolism, apoptosis, epithelial-to-mesenchymal transition, and immune infiltration<sup>[3][4]</sup>.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA